Evaluation and Management of Diffuse Sensory Peripheral Neuropathy

Diagnostic Workup

In patients with EMG‑confirmed diffuse sensory peripheral neuropathy, the initial evaluation should prioritize laboratory tests that identify treatable causes: fasting blood glucose or HbA1c, vitamin B12 with methylmalonic acid (± homocysteine), and serum protein immunofixation electrophoresis, which detects monoclonal gammopathies in ≈10 % of otherwise unexplained cases【@1】.
If fasting glucose is borderline, a glucose‑tolerance test is recommended because 25–36 % of individuals with idiopathic sensory neuropathy have impaired glucose tolerance (pre‑diabetes)【@1】.
Additional screening tests to exclude other reversible etiologies include: TSH measurement for hypothyroidism【@4】; comprehensive metabolic panel for renal disease【@5】; HIV serology when risk factors are present【@5】; and autoimmune serologies when atypical features suggest an immune‑mediated process【@6】.

Referral for advanced electrophysiological studies or nerve/skin biopsy is advised when clinical features are atypical (e.g., asymmetric distribution, rapid progression, motor predominance) or when a hereditary neuropathy is suspected; small‑fiber neuropathy may be confirmed with a skin biopsy【@7】.

Duloxetine (SNRI) – start 60 mg daily, titrate to 120 mg as needed; FDA‑approved for diabetic neuropathy with 38 % of patients achieving ≥50 % pain reduction; contraindicated in hepatic disease and also benefits comorbid depression【@6】【@4】【@9】【@11】【@8】.
Gabapentin – 300–1 200 mg three times daily, titrated slowly; Pregabalin – 100 mg three times daily (FDA‑approved for diabetic neuropathy); both require caution in patients prone to edema, unsteadiness, or falls【@6】【@4】【@11】【@8】.
Tricyclic Antidepressants – Nortriptyline or desipramine 25–75 mg at bedtime (preferred over amitriptyline for fewer anticholinergic effects); amitriptyline 10–75 mg at bedtime is also effective; number needed to treat 1.5–3.5; contraindications include glaucoma, orthostatic hypotension, cardiovascular disease, and patients >40 yr require ECG screening; maximum dose <100 mg/day; start at 10 mg/day and maintain for 6–8 weeks to assess response【@6】【@8】【@10】【@11】.

If pain persists after an adequate trial of a first‑line agent, add a medication from a different class (e.g., combine duloxetine with gabapentin)【@8】.
Opioid analgesics (tramadol 200–400 mg/day or oxycodone 20–80 mg/day) may be considered for severe or breakthrough pain【@10】【@11】.
Topical capsaicin 0.025–0.075 % applied 3–4 times daily can be used for focal pain relief【@6】【@10】.

No disease‑modifying therapies exist; all agents provide symptomatic relief only【@6】【@4】【@10】.
Optimizing glycemic control in diabetic patients may slow neuropathy progression but does not reverse existing nerve damage【@2】【@3】.
Up to 50 % of neuropathy cases are asymptomatic; pharmacologic pain treatment is reserved for symptomatic individuals【@6】【@4】.

Foot‑care education is essential for all patients: daily visual and manual foot inspection, annual 10‑g monofilament testing to identify high‑risk feet, use of well‑fitted therapeutic footwear for those with increased plantar pressure or deformities, and regular podiatric care for callus debridement and nail management【@5】【@2】【@3】.
Autonomic neuropathy screening should include assessment for gastroparesis (early satiety, nausea) and sudomotor dysfunction (abnormal sweating)【@10】【@7】.

Realistic treatment goals focus on achieving a ≥30–50 % reduction in pain intensity to improve quality of life【@8】.
Primary objectives also include preventing disease progression, foot ulceration, falls, and autonomic crises through the combined pharmacologic and non‑pharmacologic strategies outlined above【@5】.